Technical Analysis for IMVT - Immunovant, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Historical IMVT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | 0.36% | |
| Multiple of Ten Bullish | Other | 0.36% | |
| MACD Bearish Signal Line Cross | Bearish | 4.40% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.40% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.40% | |
| Doji - Bullish? | Reversal | 4.40% | |
| Multiple of Ten Bullish | Other | 4.40% | |
| Down 3 Days in a Row | Weakness | 4.40% | |
| Multiple of Ten Bullish | Other | 3.39% | |
| Wide Bands | Range Expansion | 3.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above Previous Day's High | 1 day ago | |
| Up 2% | 1 day ago | |
| 60 Minute Opening Range Breakout | 1 day ago | |
| 10 DMA Support | 2 days ago | |
| Down 2 % | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2020
- Sector: Healthcare
- Industry: Biotechnology
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Medicine Biopharmaceutical Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Transfusion Medicine Treatment Of Autoimmune Diseases Myasthenia Gravis Acquired Hemolytic Anemia
Medicine Biopharmaceutical Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Transfusion Medicine Treatment Of Autoimmune Diseases Myasthenia Gravis Acquired Hemolytic Anemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 43.9399 |
| 52 Week Low | 8.34 |
| Average Volume | 577,889 |
| 200-Day Moving Average | 24.01 |
| 50-Day Moving Average | 36.77 |
| 20-Day Moving Average | 39.80 |
| 10-Day Moving Average | 41.69 |
| Average True Range | 2.31 |
| ADX | 33.05 |
| +DI | 20.86 |
| -DI | 11.72 |
| Chandelier Exit (Long, 3 ATRs ) | 37.01 |
| Chandelier Exit (Short, 3 ATRs ) | 39.93 |
| Upper Bollinger Band | 44.67 |
| Lower Bollinger Band | 34.92 |
| Percent B (%b) | 0.7 |
| BandWidth | 24.51 |
| MACD Line | 1.58 |
| MACD Signal Line | 1.71 |
| MACD Histogram | -0.1334 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.87 | ||||
| Resistance 3 (R3) | 44.79 | 43.68 | 44.35 | ||
| Resistance 2 (R2) | 43.68 | 42.90 | 43.72 | 44.18 | |
| Resistance 1 (R1) | 42.74 | 42.42 | 43.21 | 42.82 | 44.01 |
| Pivot Point | 41.63 | 41.63 | 41.87 | 41.67 | 41.63 |
| Support 1 (S1) | 40.69 | 40.85 | 41.16 | 40.77 | 39.57 |
| Support 2 (S2) | 39.58 | 40.37 | 39.62 | 39.40 | |
| Support 3 (S3) | 38.64 | 39.58 | 39.23 | ||
| Support 4 (S4) | 38.72 |
